Geometric Engineering of Liver Organoid Culture in Pediatric Liver Diseases

C
Chao Jarasvaraparn

Primary Investigator

Enrolling By Invitation
17 years or below
All
Phase N/A
20 participants needed
1 Location

Brief description of study

What is the purpose of this study?

Chronic liver disease (CLD) in children can be caused by a variety of conditions and have serious consequences if left untreated. Liver organoids are defined as 3D structure derived from human liver tissue and is a promising new approach to treating liver disease in children and may help with disease modeling and drug testing. In this study, we propose to utilize patient derived liver organoids to model and elucidate the molecular pathophysiology of pediatric disease in children with CLDs.

THIS STUDY IS ENROLLING BY INVITATION ONLY - Subjects will be identified when their physician orders a liver biopsy to be done as standard of care and will be approached by the study team about study participation.

Detailed description of study

What will happen during the study?

  • The proposed project is designed to evaluate the role of liver organoid from children with CLDs and is a longitudinal collection of clinical data without study interventions.
  • We will start collecting liver tissue from the clinically indicated standard liver biopsy, wedge liver biopsy or explant liver from liver transplantation, prospectively, beginning in January 2025.
  • We will not request a special insertion of a needle for this liver organoid study.
  • We will bank a 5 ml blood sample collected during IV placement before liver biopsy procedure, or during routine lab draw for future studies. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic liver disease, CLD, Liver biopsy, Liver transplant, Riley
  • Age: 17 years or below
  • Gender: All

Inclusion Criteria:

  1. Children less than 18 years of age with chronic liver diseases who will undergo liver biopsy, wedge liver biopsy or liver transplant. 

    Liver diseases to be included:

  • Metabolic dysfunction-associated steatotic liver disease (MASLD)
  • Post liver transplantation
  • Fontan-associated liver disease
  • Autoimmune hepatitis
  • Primary sclerosing cholangitis
  • Wilson disease
  • Biliary atresia
  • Neonatal cholestasis
  • Alpha-1 antitrypsin deficiency
  • Alagille syndrome
  • Metabolic liver disease
  • Genetic liver disease
  • Drug induced liver injury
  • Acute liver failure
  • Non-cirrhotic portal hypertension
  • Unknow chronic liver diseases

Exclusion Criteria:

  • Inadequate biopsy size
  • Refusal of consent

Updated on 06 Mar 2025. Study ID: PGI-IIR-25843, 25843
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center